UNSPSC 51162746: Tyloxapol

This classification denotes a surface-active agent with the molecular formula (C15H22O(C2H4O)n)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y27PUL9H56, chemically known as 4-(1,1,3,3-tetramethylbutyl)phenol, polymer with formaldehyde & oxirane but more generally known as tyloxapol, which bears US NIH Compound Identifier 71388. European Medicines Agency schedules Tyloxapol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05015MIG.

World Health Organization schedules tyloxapol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TYLOXAPOL remains US FDA's Preferred Term for this commodity. Tyloxapol bears US NLM identifiers UMLS ID C0077539 and NCI Concept Code C80949. SMILES: CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1.

UNSPSC 51162746 Tyloxapol (Commodity) covers pharmaceutical and medical products that state and local governments buy for health care delivery in correctional, public health, and emergency response settings. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, soliciting parenteral products, services, and equipment — including parenteral nutrition solutions (TPN and PPN), intravenous solutions, and controlled substances — for eight correctional facilities across Washington state, with response due October 7, 2026. The scope requires documented capability to prepare and deliver IV solutions, monitor patient lab results, and adjust nutrition preparations, with strict delivery timelines (PN bags within 24 hours, other parenteral products within 8 hours). The RFQ encourages small business (25%), minority-owned (10%), women-owned (6%), and veteran-owned (5%) participation under Washington state set-aside preferences and Chapter 39.19 RCW. DOC anticipates awarding up to three contractors per region and retains discretionary extension rights through June 30, 2030. Contractors must carry commercial general liability ($1 million per occurrence / $2 million aggregate), professional liability ($2 million), business automobile liability ($1 million per occurrence), and cyber liability ($2 million).

The code also captures pharmaceutical procurement for emergency management: Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response due July 26, 2023). Recent activity is sparse and geographically limited — Washington state and Florida are the only states represented in the available record. The code shows minimal recent volume across state and local procurement, with no evidence of sustained activity across multiple jurisdictions or issuing bodies outside the correctional and community health sectors.